Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Q Biomed Inc (QBIO)

Q Biomed Inc (QBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 15
  • Shares Outstanding, K 145,095
  • Annual Sales, $ 280 K
  • Annual Income, $ -2,050 K
  • EBIT $ -3 M
  • EBITDA $ -2 M
  • 60-Month Beta 2.28
  • Price/Sales 0.05
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.09
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 06/21/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Most Recent Stories

More News
Q BioMed Inc. Provides Update to Shareholders

/PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO) a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical...

QBIO : 0.0001 (unch)
Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Patent from United States Patent Office and Notice of Allowance for Europe

/PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO) a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical...

QBIO : 0.0001 (unch)
Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Notice of Allowance for Patent from United States Patent Office

/PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO) a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical...

QBIO : 0.0001 (unch)
Q BIOMED PROVIDES SHAREHOLDER UPDATE

/PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration development company, is pleased to provide an update to its...

QBIO : 0.0001 (unch)
Q BioMed Inc. Provides Update to Shareholders

/PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO) a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical...

QBIO : 0.0001 (unch)
Q BioMed announces publication of pre-clinical research showing superior safety and efficacy against current first line therapy of its drug candidate Uttroside-B for liver cancer

/PRNewswire/ -- Q BioMed, Inc. (OTCQB: QBIO) a commercial-stage biotechnology development company announces a new publication supporting the potential superior...

QBIO : 0.0001 (unch)
Accelerated Development of COVID-19 Vaccines to Combat Potential for Possible Future Viral Pathogens and Variants

Palm Beach, FL – September 22, 2021 – FinancialNewsMedia.com News Commentary – The U.S. government, via the American Rescue Plan, is investing more than $3 billion to accelerate the discovery,...

QBIO : 0.0001 (unch)
CRVS : 8.28 (+0.49%)
MRNA : 36.59 (-0.95%)
SRNE : 0.0022 (-33.33%)
CYDY : 0.1189 (+2.24%)
Q BioMed Inc. Updates on COVID-19 Therapeutic Development and Clinical Trials – MAN-19 therapeutic program heading to clinical trial in early 2022

New York, NY –  September 22, 2021 – Q BioMed Inc. (OTCQB: QBIO ) a commercial stage biotechnology acceleration company, is pleased to provide an update on its partner asset MAN-19 for the treatment...

QBIO : 0.0001 (unch)
Global Liver Cancer Therapeutics Market Size Is Forecasted To Grow To $1.148 Billion By 2026

Palm Beach, FL – August 24, 2021 – FinancialNewsMedia.com News Commentary – Recently, approximately 1.2 million new liver cancer cases have been reporting around the world. The increasing intense...

QBIO : 0.0001 (unch)
ABVC : 0.5870 (+3.45%)
TRIL : 18.44 (+2.62%)
CASI : 5.32 (+1.14%)
SESN : 12.5760 (+7.29%)
Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Notice of Allowance for Patent in South Korea and Shows Promising Results in Initial Pre-Clinical Testing

New York, NY – August 24, 2021 – Q BioMed Inc. (OTCQB: QBIO ) a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthcare...

QBIO : 0.0001 (unch)

Business Summary

Q BioMed Inc. is a biomedical acceleration and development company. It focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. Q BioMed Inc. is based in New York.

See More

Key Turning Points

3rd Resistance Point 0.0001
2nd Resistance Point 0.0001
1st Resistance Point 0.0001
Last Price 0.0001
1st Support Level 0.0001
2nd Support Level 0.0001
3rd Support Level 0.0001

See More

52-Week High 0.0001
Fibonacci 61.8% 0.0001
Fibonacci 50% 0.0001
Fibonacci 38.2% 0.0001
Last Price 0.0001
52-Week Low 0.0001

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar